Dose density in adjuvant chemotherapy for breast cancer

Cancer Investigation

Volumn 22, Issue 4, 2004, Pages 555-568

  Citron, Marc L ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b ProHEALTH Care Associates   (United States)

Author keywords

Anticancer drug combinations; Breast cancer; Chemotherapy; Doxorubicin; Filgrastim; Neutropenia; Paclitaxel

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; DOSE RESPONSE; HAND FOOT SYNDROME; HUMAN; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; SURVIVAL ANALYSIS;

EID: 8644251751     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-200027134     Document Type: Review

References (40)

1. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998, 352 (9132), 930-942.
2. Hryniuk, W.M. The importance of dose intensity in the outcome of chemotherapy. Important Adv. Oncol. 1988, 121-141.
3. Hryniuk, W.; Frei, E., III; Wright, F.A. A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose-intensity. J. Clin. Oncol. 1998, 16 (9), 3137-3147.
4. Norton, L. Evolving concepts in the systemic drug therapy of breast cancer. Semin. Oncol. 1997, 24 (4 Suppl. 10), S10-3-S10-10.
5. Frei, E., III; Canellos, G.P. Dose: a critical factor in cancer chemotherapy. Am. J. Med. 1980, 69 (4), 585-594.
6. Bonadonna, G.; Valagussa, P.; Moliterni, A.; Zambetti, M.; Brambilla, C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N. Engl. J. Med. 1995, 332 (14), 901-906.
7. Mayers, C.; Panzarella, T.; Tannock, I.F. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 2001, 91 (17), 2246-2257.
8. Budman, D.R.; Berry, D.A.; Cirrincione, C.T.; Henderson, I.C.; Wood, W.C.; Weiss, R.B.; Ferree, C.R.; Muss, H.B.; Green, M.R.; Norton, L.; Frei, E., III. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The cancer and leukemia group B. J. Natl. Cancer Inst. 1998, 90 (16), 1205-1211.
9. Coldman, A.J.; Goldie, J.H. Impact of dose-intense chemotherapy on the development of permanent drug resistance. Semin. Oncol. 1987, 14 (4 Suppl. 4), 29-33.
10. Fisher, B.; Anderson, S.; DeCillis, A.; Dimitrov, N.; Atkins, J.N.; Fehrenbacher, L.; Henry, P.H.; Romond, E.H.; Lanier, K.S.; Davila, E.; Kardinal, C.G.; Laufman, L.; Pierce, H.I.; Abramson, N.; Keller, A.M.; Hamm, J.T.; Wickerham, D.L.; Begovic, M.; Tan-Chiu, E.; Tian, W.; Wolmark, N. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. J. Clin. Oncol. 1999, 17 (11), 3374-3388.
11. Henderson, I.C.; Berry, D.A.; Demetri, G.D.; Cirrincione, C.T.; Goldstein, L.J.; Martino, S.; Ingle, J.N.; Cooper, M.R.; Hayes, D.F.; Tkaczuk, K.H.; Fleming, G.; Holland, J.F.; Duggan, D.B.; Carpenter, J.T.; Frei, E., III; Schilsky, R.L.; Wood, W.C.; Muss, H.B.; Norton, L. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J. Clin. Oncol. 2003, 21 (6), 976-983.
12. French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J. Clin. Oncol. 2001, 19 (3), 602-611.
13. Peters, W.; Rosner, G.; Vredenburgh, J.; Shpall, E.; Crump, M.; Richardson, P.; Marks, L.; Cirrincione, C.; Wood, W.; Henderson, I.; Hurd, D.; Norton, L. A prospective, randomized comparison of two doses of combination alkylating agents as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes: preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13. Proc. ASCO 1999, 18, 1a.
14. Tallman, M.S.; Gray, R.; Robert, N.J.; LeMaistre, C.F.; Osborne, C.K.; Vaughan, W.P.; Gradishar, W.J.; Pisansky, T.M.; Petting, J.; Paietta, E.; Lazarus, H.M. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N. Engl. J. Med. 2003, 349 (1), 17-26.
15. Rodenhuis, S.; Bontenbal, M.; Beex, L.V.; Wagstaff, J.; Richel, D.J.; Nooij, M.A.; Voest, E.E.; Hupperets, P.; van Tinteren, H.; Peterse, H.L.; TenVergert, E.M.; de Vries, E.G. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N. Engl. J. Med. 2003, 349 (1), 7-16.
16. Hudis, C.; Seidman, A.; Baselga, J.; Raptis, G.; Lebwohl, D.; Gilewski, T.; Moynahan, M.; Sklarin, N.; Fennelly, D.; Crown, J.P.; Surbone, A.; Uhlenhopp, M.; Riedel, E.; Yao, T.J.; Norton, L. Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy. J. Clin. Oncol. 1999, 17 (1), 93-100.
17. Bonadonna, G.; Zambetti, M.; Valagussa, P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 1995, 273 (7), 542-547.
18. Poole, C.J.; Earl, H.M.; Dunn, J.A.; Hiller, L.; Bathers, S.; Spooner, D.; Grieve, R.; Agrawall, R.K.; Foster, E.; Twelves, C. NEAT (National Epirubicin Adjuvant Trial) and SCTBG BR9601 (Scottish Cancer Trials Breast Group) phase III adjuvant breast trials show a significant relapse-free and overall survival advantage for sequential ECMF. Proc. ASCO 2003, 22, 4.
19. Mamounas, E.P.; Bryant, J.; Lembersky, B.C.; Fisher, B.; Atkins, J.N.; Fehrenbacher, L.; Raich, P.C.; Yothers, G.; Soran, A.; Wolmark, N. Paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. Proc. ASCO 2003, 22, 4.
20. Citron, M.L.; Berry, D.A.; Cirrincione, C.; Hudis, C.; Winer, E.P.; Gradishar, W.J.; Davidson, N.E.; Martino, S.; Livingston, R.; Ingle, J.N.; Perez, E.A.; Carpenter, J.; Hurd, D.; Holland, J.F.; Smith, B.L.; Sartor, C.I.; Leung, E.H.; Abrams, J.; Schilsky, R.L.; Muss, H.B.; Norton, L. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/cancer and leukemia group B trial 9741. J. Clin. Oncol. 2003, 27 (8), 1431-1439.
21. Ellis, G.K.; Livingston, R.B.; Gralow, J.R.; Green, S.J.; Thompson, T. Dose-dense anthracycline-based chemotherapy for node-positive breast cancer. J. Clin. Oncol. 2002, 20 (17), 3637-3643.
22. Therasse, P.; Mauriac, L.; Welnicka-Jaskiewicz, M.; Bruning, P.; Cufer, T.; Bonnefoi, H.; Tomiak, E.; Pritchard, K.I.; Hamilton, A.; Piccart, M.J. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. J. Clin. Oncol. 2003, 21 (5), 843-850.
23. International Breast Cancer Study Group. Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. J. Clin. Oncol. 1996, 14 (6), 1885-1894.
24. Fumoleau, P.; Kerbrat, P.; Romestaing, P.; Fargeot, P.; Bremond, A.; Namer, M.; Schraub, S.; Goudier, M.J.; Mihura, J.; Monnier, A.; Clavere, P.; Serin, D.; Seffert, P.; Pourney, C.; Facchini, T.; Jacquin, J.P.; Sztermer, J.F.; Datchary, J.; Ramos, R.; Luporsi, E. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study group 01 trial. J. Clin. Oncol. 2003, 21 (2), 298-305.
25. Sauerbrei, W.; Bastert, G.; Bojar, H.; Beyerle, C.; Neumann, R.L.; Schmoor, C.; Schumacher, M. Randomized 2×2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients: an update based on 10 years' follow-up. The German breast-cancer study group. J. Clin. Oncol. 2000, 18 (1), 94-101.
26. Tancini, G.; Bonadonna, G.; Valagussa, P.; Marchini, S.; Veronesi, U. Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. J. Clin. Oncol. 1983, 1 (1), 2-10.
27. Falkson, H.C.; Gray, R.; Wolberg, W.H.; Gillkrist, K.W.; Harris, J.E.; Tormey, D.C.; Falkson, G. Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study. J. Clin. Oncol. 1990, 8 (4), 594-607. [Erratum in J. Clin. Oncol. 1990, 8 (9), 1603].
28. Falkson, H.C.; Gray, R.; Wolberg, W.H.; Gillkrist, K.W.; Harris, J.E.; Tormey, D.C.; Falkson, G. Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study. J. Clin. Oncol. 1990, 8 (4), 594-607. [Erratum in J. Clin. Oncol. 1990, 8 (9), 1603].
29. Jackisch, C.; Von Minckwitz, G.; Raab, G.; Schuette, M.; Blohmer, J.U.; Hilfrich, J.; Gerber, B.; Costa, S.; Merkle, E.; Eidtmann, H.; Lampe, D.; DuBois, A.; Tulusan, A.H.; Caputo, A.; Kaufmann, M. Primary endpoint analysis of the geparduo study-preoperative chemotherapy (PCT) comparing dose-dense versus sequential adriamycin/docetaxel combination in operable breast cancer (T2-3, N0-2, M0). Br. Cancer Res. Treat. 2002, 76, S50.
30. Euler, U.; Dresel, V.; Buhner, M.; Volkholz, H.; Tulusan, A.H.T. Dose and time intensified epirubicin/cyclophosphamide (EC) as preoperative treatment in locally advanced breast cancer. Br. Cancer Res. Treat. 2002, 76, S51.
31. Baldini, E.; Gardin, G.; Giannessi, P.G.; Evangelista, G.; Roncella, M.; Prochilo, T.; Collecchi, P.; Rosso, R.; Lionetto, R.; Bruzzi, P.; Mosca, F.; Conte, P.F. Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer. Ann. Oncol. 2003, 14 (2), 227-232.
32. Trudeau, M.E. Optimizing adjuvant breast cancer chemotherapy: rationale for the MA.21 study. Oncology (Huntingt.) 2001, 5 (5 Suppl. 7), 7-13.
33. Trudeau, M.E.; Clemons, M.; Charbonneau, F.; Yogendran, G.; Mehlenbacher, A.; Pritchard, D.; Deboer, G. Does adjuvant CEF require continuous prophylactic antibiotics (PAbx) to avoid febrile neutropenia (FN)? Proc. ASCO 2003, 22, 33.
34. Nabholtz, J.M.; Reese, D.M.; Lindsay, M.A.; Riva, A. Docetaxel in the treatment of breast cancer: an update on recent studies. Semin. Oncol. 2002, 29 (3 Suppl. 12), 28-34.
35. Johnston, E.; Crawford, J.; Blackwell, S.; Bjurstrom, T.; Lockbaum, P.; Roskos, L.; Yang, B.B.; Gardner, S.; Miller-Messana, M.A.; Shoemaker, D.; Garst, J.; Schwab, G. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J. Clin. Oncol. 2000, 18 (13), 2522-2528.
36. Holmes, F.A.; Jones, S.E.; O'Shaughnessy, J.; Vukelja, S.; George, T.; Savin, M.; Richards, D.; Glaspy, J.; Meza, L.; Cohen, G.; Dhami, M.; Budman, D.R.; Hackett, J.; Brassard, M.; Yang, B.B.; Liang, B.C. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann. Oncol. 2002, 13 (6), 903-909.
37. Holmes, F.A.; O'Shaughnessy, J.A.; Vukelja, S.; Jones, S.E.; Shogan, J.; Savin, M.; Glaspy, J.; Moore, M.; Meza, L.; Wiznitzer, I.; Neumann, T.A.; Hill, L.R.; Liang, B.C. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J. Clin. Oncol. 2002, 20 (3), 727-731.
38. Green, M.D.; Koelbl, H.; Baselga, J.; Galid, A.; Guillem, V.; Gascon, P.; Siena, S.; Lalisang, R.I.; Samonigg, H.; Clemens, M.R.; Zani, V.; Liang, B.C.; Renwick, J.; Piccart, M.J. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann. Oncol. 2003, 14 (1), 29-35.
39. Moore, T.D.; Patel, T.; Segal, M.L.; Zangmeister, J.; Chidiac, T.A.; Roach, R.W.; Thompson, M.E.; Larrimer, N.R. A single pegfilgrastim dose per cycle supports dose-dense (q14d) CHOP-R in patients with NHL. Blood 2002, 100 (11), 571a.
40. Younes, A.; Fayad, L.; Pro, B.; Romaguera, J.; Ha, C.S.; Wilder, R. Safety and efficacy of prophylactic pegfilgrastim in patients with hodgkin disease receiving ABVD chemotherapy. Blood 2002, 100 (11), 171b.